For patients initiating oral anticoagulant therapy, the incidence of hospitalization for upper gastrointestinal bleeding is highest and lowest with rivaroxaban and apixaban, respectively.
Your search for apixaban returned 47 results
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels
No differences seen in fracture risk in head-to-head comparisons of direct oral anticoagulants
Findings seen among older patients with incident atrial fibrillation receiving warfarin or apixaban
Risk up with amiodarone vs flecainide or sotalol among seniors with atrial fibrillation receiving apixaban or rivaroxaban.
Study of newer medications finds 16 percent receive too much or too little
Novel oral anticoagulants, that do not require the laboratory monitoring associated with warfarin therapy, may alter the landscape of venous thromboembolism treatment and stroke prevention in atrial fibrillation, according to a study presented at the 52nd American Society of Hematology Meeting and Exposition.
Compared with warfarin, dabigatran and rivaroxaban linked to lower risk of adverse renal outcomes
Investigators found an incremental increase in risks from oral anticoagulants as kidney function decreased, highlighting the need for more research to better understand bleeding risk and net benefit of treatment in the CKD population.
Bolus plus two-hour infusion of andexanet alfa cuts antifactor Xa activity by 92 percent